<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration	</title>
	<atom:link href="https://9krapalm.com/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical-trial-of-pmc-403-for-neovascular-age-related-macular-degeneration/feed/" rel="self" type="application/rss+xml" />
	<link>https://9krapalm.com/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical-trial-of-pmc-403-for-neovascular-age-related-macular-degeneration/</link>
	<description>เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm</description>
	<lastBuildDate>Tue, 15 Oct 2024 02:50:00 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>
</channel>
</rss>
